Patents Examined by Claire M. Kaufman
  • Patent number: 10052370
    Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 21, 2018
    Assignees: ICON GENETICS GMBH, UNIVERSITY OF SOUTHAMPTON
    Inventors: Natalia Savelyeva, Franziska Jarczowski, Romy Kandzia, Anja Nickstadt, Frank Thieme, Victor Klimyuk, Yuri Gleba, Duc Bui-Minh, Freda K. Stevenson, Warayut Chotprakaikiat
  • Patent number: 7452538
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: November 18, 2008
    Assignees: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Patent number: 7312315
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: December 25, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7304134
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: December 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7304138
    Abstract: This invention relates to therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids, and on their role in the signaling pathway relating to endothelial cell migration and/or differentiation. In addition, this invention provides a substantially purified Jagged protein, as well as a substantially purified nucleic acid or segment thereof encoding Jagged protein, or a functionally equivalent derivative, or allelic or species variant thereof. Further, this invention provides a substantially purified soluble Jagged protein and a substantially purified nucleic acid encoding same as well as a recombinant cell comprising a nucleic acid encoding a soluble Jagged protein. Soluble Jagged provides further therapeutic and diagnostic methods relating to diseases, disorders, and conditions involving Jagged/Notch signaling including, inter alia, angiogenesis, differentiation, and control of gene expression.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: December 4, 2007
    Assignee: Maine Medical Center Research Institute
    Inventors: Thomas Maciag, Ann B. Zimrin, Deena J. Small, Igor A. Prudovsky
  • Patent number: 7294495
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: November 13, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7294705
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: November 13, 2007
    Assignee: Genetech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7282365
    Abstract: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhHER2/neu and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: October 16, 2007
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Paolo Monaci, Maurizio Nuzzo, Nicola La Monica, Gennaro Ciliberto, Armin Lahm
  • Patent number: 7282566
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: October 16, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7279160
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: October 9, 2007
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. Lobuglio, Donald J. Buchsbaum
  • Patent number: 7273926
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: September 25, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7252994
    Abstract: Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.
    Type: Grant
    Filed: June 29, 2002
    Date of Patent: August 7, 2007
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Kyung Jin Kim
  • Patent number: 7247451
    Abstract: The invention is drawn to anti-thrombin proteins from the salivary glands of the species, Simulium. Methods for recombinant production of the protein as well as biomedical uses are provided.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: July 24, 2007
    Assignee: Auburn University
    Inventors: Mary S. Cupp, Eddie W. Cupp
  • Patent number: 7244429
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: July 17, 2007
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Patent number: 7238499
    Abstract: The present invention relates, in part, to a polypeptide domain having reduced immunogenicity that is capable of inducing trimers in heterologous polypeptides, fusion polypeptides comprising the trimer inducing domain, nucleic acids encoding the polypeptides of the invention and methods of making and using the same.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: July 3, 2007
    Assignee: Immunex Corporation
    Inventor: Pranhitha Reddy
  • Patent number: 7220841
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: May 22, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • Patent number: 7196173
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: March 27, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • Patent number: 7196174
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: March 27, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood, Colin K. Watanabe
  • Patent number: 7179887
    Abstract: This invention relates to nucleic acid encoding guinea pig PAR 4 and to the protein encoded thereby. The guinea pig DNA and protein are useful for the development of models of human platelet aggregation. The invention further relates to an animal model to assess the role of PAR antagonists in thrombosis.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: February 20, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew L. Darrow, Claudia K. Derian, Michael F. Addo, Patricia Andrade-Gordon
  • Patent number: 7169573
    Abstract: The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 30, 2007
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Shinichiro Kurosawa, Deborah J. Stearns-Kurosawa